Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Allogene
Biotech
Allogene’s lymphoma data show CAR-T could ‘leapfrog’ competition
“We continue to believe cema-cel has the potential to leapfrog other autologous and allogeneic CD19 CAR-T therapies,” William Blair analysts said.
James Waldron
Feb 14, 2025 10:35am
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Nov 14, 2024 5:59am
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Nov 8, 2024 4:47am
How to get cell therapies flying off-the-shelf
May 31, 2024 9:00am
Cell therapy reckoning: An unmet need remains in oncology
May 30, 2024 10:00am
A biotech reckoning: 'We've lost our luster in cell therapies'
May 29, 2024 10:22am
